MDx Firm AutoGenomics Withdraws IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics filed with the US Securities and Exchange Commission to officially withdraw a planned initial public offering.

In a document filed on Friday, the Vista, Calif.-based firm did not cite a reason, saying only that it "has elected not to pursue the sale of securities" pursuant to its registration statement filed in September 2012. The company had intended to raise as much as $65 million in its IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.